Article du mois de Mai

Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients.

BACKGROUND:

The use of web-based monitoring for lung cancer patients is growing in interest because of promising recent results suggesting improvement in cancer and resource utilization outcomes. It remains an open question whether the overall survival (OS) in these patients could be improved by using a web-mediated follow-up rather than classical scheduled follow-up and imaging.

Article du mois d’Avril

Osimertinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for both EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. AURA (NCT01802632) is a phase I/II clinical trial to determine the dose, safety, and efficacy of osimertinib. This article reports the results from the phase II extension component.

Article du mois de Mars

Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.

Pneumonitis is an uncommon but potentially fatal toxicity of anti–programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) monoclonal antibodies (mAbs). Clinical, radiologic, and pathologic features are poorly described.

 

Article du mois de janvier

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

Abstract

Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. Methods We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 weeks (four intravenous infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularly at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group).

Article du mois de novembre

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Langer CJ1, Gadgeel SM2, Borghaei H3, Papadimitrakopoulou VA4, Patnaik A5, Powell SF6, Gentzler RD7, Martins RG8, Stevenson JP9, Jalal SI10,Panwalkar A11, Yang JC12, Gubens M13, Sequist LV14, Awad MM15, Fiore J16, Ge Y16, Raftopoulos H16, Gandhi L17; KEYNOTE-021 investigators.

Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.

Articles du mois d’octobre

Paula Mulvenna, Matthew Nankivell, Rachael Barton, Corinne Faivre-Finn, Paula Wilson, Elaine McColl, Barbara Moore, Iona Brisbane,
David Ardron, Tanya Holt, Sally Morgan, Caroline Lee, Kathryn Waite, Neil Bayman, Cheryl Pugh, Benjamin Sydes, Richard Stephens,
Mahesh K Parmar, Ruth E Langley
Lancet 2016; 388: 2004–14
Cécile Le Pechoux, Frederic Dhermain, Benjamin Besse
www.thelancet.com Vol 388 October 22, 2016
Vassiliki Papadimitrakopoulou, J. Jack Lee, Ignacio I. Wistuba, Anne S. Tsao, Frank V. Fossella, Neda Kalhor,
Sanjay Gupta, Lauren Averett Byers, Julie G. Izzo, Scott N. Gettinger, Sarah B. Goldberg, Ximing Tang,
Vincent A. Miller, Ferdinandos Skoulidis, Don L. Gibbons, Li Shen, Caimiao Wei, Lixia Diao, S. Andrew Peng,
Jing Wang, Alda L. Tam, Kevin R. Coombes, Ja Seok Koo, David J. Mauro, Eric H. Rubin, John V. Heymach,
Waun Ki Hong, and Roy S. Herbst
J Clin Oncol 34:3638-3647. © 2016 by American Society of Clinical Oncology

Article du mois de novembre

Prospective and clinical validation of ALK immunohistochemistry: Results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

K. TakeuchiTakeuchi Takeuchi Takeuchi1, 2, Y. TogashiTogashi Togashi 1, 2, Y. Kamihara Kamihara Kamihara 3, T. Fukuyama 3, H. YoshiokaYoshioka YoshiokaYoshioka4, A. Inoue 5, H. Katsuki Katsuki KatsukiKatsuki3, K. Kiura Kiura 6, K. Nakagawa Nakagawa7, T. Seto 8, M. Maemondo MaemondoMaemondo 9, T. Hida Hida 10 , M. Harada Harada 11 , Y. Ohe 12 , N. Nogami 13, N. YamamotoYamamoto Yamamoto 14 , M. Nishio 15, T. TamuraTamura 16

 

Annals of Oncology Advance Access published October 20, 2015

Article du mois d’Octobre

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz‑Ares, L. Horn, D.R. Spigel, M. Steins, N.E. Ready, L.Q. Chow,
E.E. Vokes, E. Felip, E. Holgado, F. Barlesi, M. Kohlhäufl, O. Arrieta, M.A. Burgio,
J. Fayette, H. Lena, E. Poddubskaya, D.E. Gerber, S.N. Gettinger, C.M. Rudin,
N. Rizvi, L. Crinò, G.R. Blumenschein, Jr., S.J. Antonia, C. Dorange,
C.T. Harbison, F. Graf
Finckenstein, and J.R. Brahmer
New England Journal of Medicine (Impact Factor: 55.87). 09/2015